Skip to main content
Premium Trial:

Request an Annual Quote

Lesaffre Acquires Recombia Biosciences

NEW YORK – France's Lesaffre said on Wednesday that it has acquired genome engineering firm Recombia Biosciences.

The deal "is part of a comprehensive strategy to invest heavily in research and development to unlock the full potential of microorganisms, such as yeast or beneficial bacteria," Lesaffre, a major yeast manufacturer that also operates nutrition and industrial biotechnology businesses, said in a statement.

Recombia, a Stanford University spinout, will keep its name and remain at its Brisbane, California, headquarters while joining the Lesaffre Bioengineering Center of Excellence. The firm has exclusively licensed four genome engineering technologies from Stanford.

Financial and other details were not disclosed.

The deal builds on a strategic partnership between the firms started in 2020 to design and develop yeasts for production of fermented ingredients and biofuels.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.